The report features inputs from a number of eminent industry stakeholders, according to whom, the maximum opportunity within this domain is likely to be associated with STING pathway modulators that are being developed for the treatment of oncological disorders. The report features detailed transcripts of discussions held with the following experts:
Glen Barber (Chief Executive Officer, STINGINN)
Kryzsztof Brzozka (Chief Scientific Officer, Ryvu Therapeutics)
The research covers detailed profiles of key players (illustrative list provided below) engaged in the development of STING agonists; each profile features an overview of the developer, details related to its financial performance (if available), product description, recent developments, and an informed future outlook.
Bristol Myers Squibb
Spring Bank Pharmaceuticals
For additional details, please visit